An observational study in Parkinson Disease and Temperature Sensivity, sponsored by Acibadem University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Acibadem University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.
Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 12th largest by planned enrollment of the 73 observational ones that give a count, is one of 29 that started in 2026, is one of 73 observational ones, reaches primary completion later than 37 of the 55 other live ones, and was the 164th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:
Mustafa Kemal University · Sites in Turkey
Ages 35–75 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 40+
Kahramanmaras Sutcu Imam University · Sites in Turkey
Ages 40–75
Medipol University · Sites in Turkey
Ages 50–80
Ankara University · Sites in Turkey
Ages 40–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
172 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 32 across the 99 interventional studies, 61 across the 73 observational. Of the 104 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 172 have an industry lead sponsor. The 10 most frequent:
Acibadem University is the lead sponsor of 222 studies on the registry; 51 are open to participants now.
Acibadem University has 5 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
18 of the studies in Parkinson Disease with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678983Izmir Bakircay UniversityWhole-Body Vibration in Parkinson Disease | 2026-12 |
| NCT06154356Karamanoğlu Mehmetbey UniversityAction Observation and Motor Imagery Therapy in Parkinson's Disease | 2026-12 |
| NCT07730073Atlas UniversityEfficacy of LSVT-LOUD Therapy on Voice, Speech, and Quality of Life in Parkinson's Disease | 2026-12 |
| NCT07010783Ankara UniversityRespiratory Functions in Parkinson's Disease | 2026-12-01 |
| NCT07641556Saglik Bilimleri UniversitesiThe Effects of Tele-Rehabilitation-Based Dual-Task Upper Extremity Training in Patients With Parkinson's Disease | 2026-12-01 |
Add all 18 to your calendar (.ics) → With an account.
Among the 172 studies in Parkinson Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to examine the validity and reliability of the Turkish version of the Heat Sensitivity Scale in individuals with Parkinson's disease. This cross-sectional methodological study will evaluate the psychometric properties of the scale, including internal consistency, test-retest reliability, and construct validity, in order to provide a valid and reliable tool for assessing temperature sensitivity in Turkish-speaking individuals with Parkinson's disease.
The study population will consist of individuals with clinically diagnosed Parkinson's disease (Hoehn and Yahr stage 1-3), aged between 40 and 85 years, with adequate cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department. The study population represents ambulatory individuals with mild to moderate disease severity suitable for comprehensive biopsychosocial assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Heat Sensitivity Scale Total Score
Heat sensitivity will be assessed using the Turkish version of the Heat Sensitivity Scale in individuals with Parkinson's disease. The scale evaluates symptoms related to heat sensitivity and their impact on daily life. The total score ranges from 29 to 116, with higher scores indicating greater heat sensitivity-related problems and therefore a worse outcome. Psychometric properties, including internal consistency, test-retest reliability, and construct validity, will be analyzed.
Time frame: Baseline (at the time of questionnaire administration)
Parkinson's Disease Questionnaire-39 (PDQ-39) Total and Subscale Scores
Quality of life will be assessed using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated self-report measure specific to Parkinson's disease. The questionnaire consists of 39 items across 8 domains, including mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. Scores can be transformed to a 0-100 scale, with higher scores indicating worse quality of life. PDQ-39 scores will be used to evaluate the construct validity of the Turkish version of the Temperature Sensitivity Scale.
Time frame: Baseline (at the time of questionnaire completion)
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.